Medigene AG

MDG1

Company Profile

  • Business description

    Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

  • Contact

    Lochhamer Strasse 11
    Martinsried
    PlaneggBY82152
    DEU

    T: +49 892000330

    E: [email protected]

    https://www.medigene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    87

Stocks News & Analysis

stocks

Competition impacting ASX market darling

Shares tumble after results.
stocks

Ask the analyst: Is the market underestimating Bapcor?

This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
stocks

Is our ASX best idea still attractive after shares surge?

Shares rose over 21% following the results. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,752.504.900.06%
CAC 408,006.2233.190.42%
DAX 4021,911.74124.740.57%
Dow JONES (US)44,470.41167.010.38%
FTSE 1008,767.8067.270.77%
HKSE21,395.73126.25-0.59%
NASDAQ19,714.27190.870.98%
Nikkei 22538,801.1714.150.04%
NZX 50 Index12,917.4541.100.32%
S&P 5006,066.4440.450.67%
S&P/ASX 2008,485.002.200.03%
SSE Composite Index3,316.835.34-0.16%

Market Movers